Posted by Michael Wonder on 12 Feb 2018
NICE asks Tesaro to submit CDF application for Zejula
9 February 2018 - Tesaro has been asked by NICE to submit a proposal for Zejula use on the National Health Service via the Cancer Drugs Fund for maintenance treatment of patients with relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
The drug was approved by European regulators in November last year for patients in a complete response (CR) or partial response (PR) to platinum-based chemotherapy.
Zejula (niraparib) is the first once-daily, oral poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor to be cleared in the region for patients regardless of BRCA mutation status.
